Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200324046850N2
IRCT20200324046850N2
Completed
Phase 2

Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms

Abadan University of Medical Sciences0 sites62 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19.2019-nCOV diseaseU07.1

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
COVID-19.
Sponsor
Abadan University of Medical Sciences
Enrollment
62
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abadan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •COVID\-19 patients that have positive PCR test of nasopharyngeal sample or have bilateral multi\-lobar ground glass opacity in CT scan
  • •O2 saturation under 94% or respiratory rate above 24 or decreased level of consciousness

Exclusion Criteria

  • •patients under 18 years
  • •pregnant or breast feeding women
  • •patients did not consent to participate in the study
  • •patients who took any complementary medicine
  • •safety problem for patients
  • •patients with any allergy or hypersensitivity to Sofosbuvir \+ Daclatasvir or Ribavirin or with major interaction with other medicine

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19
IRCT20200624047908N1Abadan University of Medical Sciences1,000
Completed
Not Applicable
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldHealth Condition 1: B182- Chronic viral hepatitis CHealth Condition 2: D56- Thalassemia
CTRI/2020/06/025910Riten Kumar Samadder70
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCV
IRCT20080901001155N30Rasht University of Medical Sciences16
Completed
Not Applicable
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.
IRCT20170614034526N3Jinnah Hospital, Lahore36
Not yet recruiting
Not Applicable
Investigating the in vivo bioequivalence of Sofosbuvir/Daclatasvir tabletIn the present study, the products will be administered to healthy volunteers..
IRCT20220211053992N8Tabriz University of Medical Sciences24